The use of liquid biopsy is of great relevance for the management of advanced NSCLC, enabling the identification of KRAS mutations at the baseline, but also to picture disease heterogeneity, to evaluate response to treatment in time and to identify molecular mechanisms of resistance to targeted molecules [22,23,24]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.